Breaking News
Israel Vetoes Trump in the Middle East--Again
Gen Z, the new 'Silent Generation,' swaps smartphones for dumb ones…
How The World Views China Vs The US In 2026
Can Sam Altman Be Trusted Inside Your Home? Meet OpenAI's New Always-On Smart Speaker
Top Tech News
What could possibly go wrong? Scientists use AI to design new viruses
Dual-motor suitcase drive underpins 3,000-hp hypercar
DoorDash Wins Federal Approval To Fly Its Own Delivery Drones
Shade-Resistant Solar Cells Retain 97% Efficiency After 2,000 Hours of Testing
20 Ancient Engineering SECRETS
Stonehenge Was Reanalyzed by AI -- And the Findings Are Hard to Explain
After Years Of Delays, Aptera Is Finally Preparing To Build Customer Cars
'When you kill it, it doesn't die': the jellyfish that has cracked the secret of immorta
Archer Aviation debuts Halo autonomous VTOL, Thunder's commercial twin
US Telecoms Slide On Starlink Mobile Threat; Bernstein Sees It As A "Jab, But No Knockout Yet**
Nanotech platform Carries mRNA Directly to Target Cells
The groundbreaking method may prove useful in treating myriad malignancies, inflammatory diseases and rare genetic disorders.
Lipid nanoparticles (LNP) were used to deliver modified messenger RNA to treat inflammatory bowel diseases and other diseases.
Prof. Dan Peer, Molecular Cell Biology at TAU's Faculty of Life Sciences, led the research for the new study.
Over the past few years, lipid carriers encapsulating messenger RNAs (mRNAs) have been shown to be extremely useful in altering the protein expressions for a host of diseases. But directing this information to specific cells has remained a major challenge.
"In our new research, we utilized mRNA-loaded carriers — nanovehicles carrying a set of genetic instructions via a biological platform called ASSET — to target the genetic instructions of an anti-inflammatory protein in immune cells," says Prof. Peer.